Tacrolimus rescue therapy in resistant or relapsing cases of primary glomerulonephritis

Journal of Nephrology

Volumn 21, Issue 5, 2008, Pages 713-721

  Arikan, Hakki ^a   Koc, Mehmet ^a   Cakalagaoglu, Fulya ^a   Eren, Zehra ^a   Segal, Mark S ^b   Tuglular, Serhan ^a   Ozener, Cetin ^a   Akoglu, Emel ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Primary glomerulonephritis; Proteinuria; Tacrolimus

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUCONAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; SERUM ALBUMIN; STEROID; TACROLIMUS; CREATININE; IMMUNOSUPPRESSIVE AGENT;

ADD ON THERAPY; ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; GLOMERULONEPHRITIS; HUMAN; HYPERLIPIDEMIA; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOGLOBULIN M NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; LOW DRUG DOSE; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTOXICITY; OROPHARYNX CANDIDIASIS; PROTEINURIA; RELAPSE; REMISSION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; BLOOD; MIDDLE AGED; RECURRENT DISEASE; URINE;

ADULT; CREATININE; FEMALE; GLOMERULONEPHRITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROTEINURIA; RECURRENCE; REMISSION INDUCTION; TACROLIMUS; YOUNG ADULT;

EID: 63249120080     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Torres A, Dominguez-Gil B, Carreno A, et al. Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. Kidney Int. 2002;61:219-227.
2. Rydell JJ, Korbet SM, Borak RZ, Schwartz MM. Focal glomerular sclerosis in adults: presentation, course and response to treatment. Am J Kidney Dis. 1995;25:534-542.
3. Praga M, Hernandez E, Montoya C, Andres A, Ruilope LM, Rodicio JL. Long-term beneficial effects of angiotensin converting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis. 1992;20:240-248.
4. Cattran DC, Appel GB, Hebert LA, et al. A randomised trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. Kidney Int. 1999;56:2220-2226.
5. Cattran DC, Greenwood C, Ritchie S, et al. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Kidney Int. 1995;47:1130-1135.
6. Mahmoud I, Basuni F, Sabry A, et al. Single-centre experience with cyclosporin in 106 children with idiopathic focal segmental glomerulosclerosis. Nephrol Dial Transplant.. 2005;20:735-742.
7. Myers BD, Newton L. Cyclosporine-induced chronic nephropathy: an obliterative microvascular injury. J Am Soc Nephrol. 1991;2(Suppl 1):S45-S52.
8. McCauley J, Shapiro R, Ellis D, Igdal H, Tzakis A, Starzl TE. Pilot trial of FK 506. in the management of steroid-resistant nephrotic syndrome. Nephrol Dial Transplant. 1993;8:1286-1290.
9. Schweda F, Liebl R, Riegger GA, Kramer BK. Tacrolimus treatment for sterod- and cyclosporine-resistant minimal-change nephrotic syndrome. Nephrol Dial Transplant. 1997;12:2433-2435.
10. Segarra A, Vila J, Pou L, et al..Combined therapy of tacrolimus and corticosteroids in cyclosporine-resistant or dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up. Nephrol Dial Transplant. 2002;17:655-662.
11. Duncan N, Dhaygucle A, Owen J, et al. Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol Dial Transplant. 2004; 19:3062-3067.
12. Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet. 1999;353:1083-1091.
13. Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis: a report of the International Study of Kidney Disease in Children. Pediatr Nephrol. 1996;10:590-593.
14. Szeto CC, Leung CB, Lai FM, Li PK. Tacrolimus in resistant primary membranous nephropathy: a report of 3 cases. Clin Nephrol. 2003;59:293-296.
15. Cattran DC, Appel GB, Hebert LA, et al; North America Nephrotic Syndrome Study Group. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int. 2001;59:1484-1490.
16. Chen D, Jefferson B, Harvey SJ, et al. Cyclosporine a slows the progressive renal disease of Alport syndrome (X-linked hereditary nephritis): results from a canine model. J Am Soc Nephrol. 2003; 14:690-698.
17. Ambalavanan S, Fauvel JP Sibley RK, Myers BD. Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy. J Am Soc Nephrol. 1996;7:290-298.
18. Zietse R, Wenting GJ, Kramer P, Schalekamp MA, Weimar W. Effects of cyclosporin A on glomerular barrier function in the nephrotic syndrome. Clin Sci (Lond). 1992;82:641-650.
19. Meyrier A, Noel LH, Auriche P, Callard P. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Societe de Nephrologie. Kidney Int. 1994;45:1446-1456.
20. Ghiggeri GM, Catarsi P, Scolari F, et al. Cyclosporine in patients with steroid-resistant nephrotic syndrome: an open-label, nonrandomized, retrospective study. Clin Ther. 2004;26:1411-1418.